Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Mycophenolate mofetil is a potent antimetabolite immunosuppressant used to prevent organ rejection in transplant recipients by inhibiting the proliferation of T and B lymphocytes.
Name
Mycophenolate Mofetil
Raw Name
MYCOPHENOLATE MOFETIL
Category
Other
Drug Count
5
Variant Count
65
Last Verified
February 17, 2026
RxCUI
199058, 200060, 213394, 311880, 311881, 616435, 616444, 616447, 2684851
UNII
9242ECW6R0, UXH81S8ZVB
About Mycophenolate Mofetil
Mycophenolate mofetil is a potent antimetabolite immunosuppressant used to prevent organ rejection in transplant recipients by inhibiting the proliferation of T and B lymphocytes.
Detailed information about Mycophenolate Mofetil
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Mycophenolate Mofetil.
Healthcare providers typically prescribe mycophenolate mofetil in combination with other medications, such as corticosteroids (like prednisone) and calcineurin inhibitors (like cyclosporine or tacrolimus), to create a multi-pronged defense against the immune system's natural tendency to attack a foreign organ. While its primary FDA-approved role is in kidney, heart, and liver transplantation, it is also frequently used 'off-label' (a use not specifically approved by the FDA but supported by clinical evidence) for various autoimmune conditions, including lupus nephritis, systemic vasculitis, and certain types of refractory (difficult to treat) rheumatoid arthritis.
To understand how mycophenolate mofetil works, one must look at the basic biology of how cells divide. For immune cells—specifically T-lymphocytes and B-lymphocytes—to multiply and attack a transplanted organ, they must create new DNA. A critical component of DNA is a molecule called guanosine. Most cells in the human body have two different pathways to create guanosine: the 'de novo' pathway (building it from scratch) and the 'salvage' pathway (recycling old parts).
However, T and B lymphocytes are unique because they rely almost exclusively on the 'de novo' pathway to produce guanosine. Mycophenolic acid (the active form of the drug) specifically inhibits an enzyme called inosine monophosphate dehydrogenase (IMPDH). This enzyme is the 'bottleneck' or the most important step in the de novo pathway. By blocking this enzyme, mycophenolate mofetil effectively starves the lymphocytes of the guanosine they need to replicate. Because other cells in the body can use the 'salvage' pathway, they are much less affected by the drug. This selectivity is why mycophenolate mofetil is often preferred over older, more toxic drugs; it specifically targets the cells responsible for organ rejection while sparing many other types of tissue.
Understanding the pharmacokinetics (how the body moves and processes the drug) of mycophenolate mofetil is essential for ensuring it stays at therapeutic levels without becoming toxic.
Mycophenolate mofetil is FDA-approved for the prophylaxis (prevention) of organ rejection in patients receiving the following:
Beyond these approved uses, clinical guidelines from organizations like the American College of Rheumatology often recommend mycophenolate mofetil for 'off-label' conditions such as:
Mycophenolate mofetil is available in several formulations to accommodate different patient needs:
> Important: Only your healthcare provider can determine if Mycophenolate Mofetil is right for your specific condition. This medication requires close medical supervision and frequent blood tests to ensure safety and efficacy.
The dosage of mycophenolate mofetil is highly individualized based on the organ transplanted and the other medications being taken. Healthcare providers typically use the following standard ranges:
For children undergoing kidney transplantation, the dose is usually calculated based on their Body Surface Area (BSA):
For patients with chronic severe renal impairment (defined as a glomerular filtration rate less than 25 mL/min/1.73 m²) who are outside of the immediate post-transplant period, doses greater than 1 gram twice daily should be avoided. These patients must be monitored very closely for signs of toxicity.
For patients with severe liver parenchymal disease, no specific dose adjustments are usually required for kidney transplants. However, the effect of hepatic disease on the metabolism of the drug in other transplant types is less clear, and careful monitoring is necessary.
Clinical studies have not identified significant differences in responses between the elderly and younger patients. However, older adults may be at a higher risk for certain side effects, such as infections or gastrointestinal bleeding, due to age-related changes in kidney function or the presence of other medical conditions.
To get the most benefit from this medication, it must be taken exactly as prescribed:
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose (within 2 hours), skip the missed dose and return to your regular schedule. Never take two doses at once to make up for a missed one, as this significantly increases the risk of toxicity.
Signs of a mycophenolate mofetil overdose may include severe nausea, vomiting, diarrhea, and a dangerous drop in white blood cell counts (increasing infection risk). In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Because the drug undergoes enterohepatic recirculation, treatments that bind the drug in the gut (like bile acid sequestrants) may be used by medical professionals to help clear the drug from the body.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without direct medical guidance, as doing so can lead to organ rejection.
Because mycophenolate mofetil suppresses the immune system and affects rapidly dividing cells, side effects are common. Many patients experience:
> Warning: Stop taking Mycophenolate Mofetil and call your doctor or seek emergency care immediately if you experience any of the following:
Taking mycophenolate mofetil for a long period increases certain risks:
The FDA has issued several 'Black Box' warnings for mycophenolate mofetil, which are the most serious warnings for a medication:
Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular monitoring of blood counts is essential to catch side effects early.
Mycophenolate mofetil is a high-alert medication that requires significant precautions. Patients must be aware that while this drug is vital for preventing organ rejection, it significantly alters the body's ability to fight off environmental threats and internal cellular errors.
According to the FDA-approved labeling, Mycophenolate Mofetil carries the following critical warnings:
To ensure the drug is working safely, your healthcare provider will require frequent laboratory tests:
Mycophenolate mofetil may cause dizziness, confusion, or somnolence (sleepiness) in some patients. You should observe how the medication affects you before driving or operating heavy machinery.
There is no direct chemical interaction between alcohol and mycophenolate mofetil; however, alcohol can worsen certain side effects like dizziness and stomach irritation. Furthermore, alcohol can strain the liver, which is responsible for processing many transplant medications. Discuss your alcohol consumption with your doctor.
You must never stop taking mycophenolate mofetil suddenly. Doing so can cause your immune system to immediately attack your transplanted organ, leading to organ failure. If the drug must be stopped due to severe side effects, your doctor will manage the transition to a different immunosuppressant.
> Important: Discuss all your medical conditions, including any history of ulcers, kidney disease, or viral infections, with your healthcare provider before starting Mycophenolate Mofetil.
Mycophenolate mofetil does not typically interfere with common laboratory chemical tests, but its effect on white blood cell counts will be reflected in every CBC (Complete Blood Count) test. It is important for the lab to know you are on this medication when interpreting these results.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even over-the-counter medications like aspirin or ibuprofen can interact with your transplant regimen.
Mycophenolate mofetil must NEVER be used in the following circumstances:
These are conditions where the drug may be used, but only with extreme caution and a careful risk-benefit analysis by a specialist:
Patients who have had an adverse reaction to Myfortic (mycophenolic acid) will likely have the same reaction to CellCept (mycophenolate mofetil), as they both result in the same active molecule in the bloodstream. There is no known cross-sensitivity with other classes of immunosuppressants like tacrolimus or azathioprine.
> Important: Your healthcare provider will evaluate your complete medical history, including any rare genetic conditions, before prescribing Mycophenolate Mofetil.
Mycophenolate mofetil is one of the most dangerous medications to take during pregnancy. It is classified as having high teratogenic potential. According to data from the National Transplantation Pregnancy Registry, approximately 45% to 49% of pregnancies exposed to MMF end in miscarriage, compared to 12-15% in the general population. Of the babies born alive, about 23% to 27% have structural birth defects, including:
Females of childbearing potential must have two negative pregnancy tests before starting the drug and must use two forms of effective contraception during treatment and for 6 weeks after stopping the drug.
It is not known if mycophenolate mofetil passes into human breast milk. However, because of the potential for serious adverse reactions in the nursing infant (such as immune suppression and cancer risk), breastfeeding is not recommended while taking this medication.
Mycophenolate mofetil is FDA-approved for use in children aged 2 years and older for kidney transplant rejection prevention. The safety and efficacy in pediatric heart and liver transplant recipients have not been established in large-scale trials, though it is used in clinical practice. Children may be more sensitive to the side effects, particularly diarrhea and infections.
In patients over age 65, the risk of side effects is generally higher. Elderly patients are more likely to develop serious infections, gastrointestinal bleeding, and pulmonary edema (fluid in the lungs) compared to younger patients. Dose adjustments are not always necessary based on age alone, but doctors will monitor these patients more frequently.
For patients with severe chronic renal impairment (GFR < 25 mL/min/1.73 m²), the levels of the drug's metabolites can increase significantly. These patients should be limited to a maximum dose of 1 gram twice daily and monitored closely for signs of neutropenia (low white blood cells).
In patients with severe liver disease (such as biliary atresia or cirrhosis), the processing of the drug is generally unaffected for kidney transplant patients. However, for liver transplant patients, the presence of hepatic disease may complicate the interpretation of drug levels and side effects.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or have underlying kidney or liver issues.
Mycophenolate mofetil is the 2-ethyl ester of mycophenolic acid (MPA). MPA is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). It specifically targets the Type II isoform of IMPDH, which is highly expressed in proliferating lymphocytes. By inhibiting this enzyme, MPA prevents the de novo synthesis of guanosine nucleotides. Since T and B lymphocytes cannot use the salvage pathway for guanosine synthesis, they are unable to replicate their DNA, leading to a halt in cell division (cytostatic effect). Additionally, MPA can induce apoptosis (programmed cell death) in activated T-lymphocytes and inhibit the glycosylation of adhesion molecules, which prevents lymphocytes from migrating to the site of the transplanted organ.
The primary pharmacodynamic effect is the suppression of the immune response. The onset of action is relatively rapid, with IMPDH inhibition occurring shortly after the first dose. However, the full clinical effect in preventing organ rejection is only achieved when the drug reaches 'steady state' in the blood, which takes several days of consistent dosing.
| Parameter | Value |
|---|---|
| Bioavailability | 94% |
| Protein Binding | 97% (to Albumin) |
| Half-life | ~17.9 hours |
| Tmax (Time to peak) | 0.8 to 1.3 hours |
| Metabolism | Liver/GI (to MPA), then Liver (to MPAG) |
| Excretion | Renal 93%, Fecal 6% |
Mycophenolate mofetil is classified as an antimetabolite immunosuppressant. It is distinct from calcineurin inhibitors (like tacrolimus) and mTOR inhibitors (like sirolimus) because it specifically interferes with DNA synthesis rather than cell signaling pathways. It is often considered a 'steroid-sparing' agent because its use allows doctors to prescribe lower doses of prednisone, reducing long-term steroid side effects.
Medications containing this ingredient
Common questions about Mycophenolate Mofetil
Mycophenolate mofetil is primarily used to prevent the body from rejecting a transplanted organ, such as a kidney, heart, or liver. It works by suppressing the immune system, specifically the T and B cells that would otherwise attack the new organ. Healthcare providers often prescribe it in combination with other medications like cyclosporine and corticosteroids for a comprehensive approach. Beyond transplants, it is also used off-label for autoimmune diseases like lupus nephritis and certain types of vasculitis. Because it is a potent drug, it is only used for serious conditions under the guidance of a specialist.
The most common side effects involve the digestive system and the blood. Many patients experience diarrhea, nausea, vomiting, and stomach pain, which can sometimes be managed by adjusting the timing of doses. It also frequently causes a drop in white blood cell counts (leukopenia), which increases the risk of catching infections. Other common issues include high blood pressure, swelling in the legs (edema), and headaches. Because of these risks, patients must undergo regular blood tests to ensure their levels remain within a safe range.
While there is no known direct chemical interaction between alcohol and mycophenolate mofetil, it is generally advised to limit alcohol consumption. Alcohol can irritate the stomach lining, potentially worsening the gastrointestinal side effects like nausea or diarrhea caused by the medication. Additionally, alcohol can put extra stress on the liver, which is already working hard to process your various transplant medications. Chronic alcohol use can also weaken the immune system further, complicating your recovery. Always consult your transplant team before consuming alcohol to ensure it is safe for your specific health status.
No, mycophenolate mofetil is highly dangerous during pregnancy and carries a 'Black Box' warning for embryofetal toxicity. Exposure during the first trimester leads to a very high rate of miscarriage and can cause severe birth defects involving the ears, face, heart, and limbs. Women of childbearing age must use two forms of effective birth control while taking this drug and for six weeks after stopping it. If you discover you are pregnant while taking this medication, you must contact your doctor immediately. There is a specific REMS program in place to help manage these risks and educate patients.
Mycophenolate mofetil begins to inhibit the enzymes in your immune cells within hours of the first dose. However, it takes several days of consistent twice-daily dosing to reach a 'steady state' where the drug levels in your blood remain constant. In terms of clinical results, it is a long-term preventative medication rather than a 'fast-acting' cure. For conditions like lupus nephritis, it may take 3 to 6 months of continuous therapy before a significant improvement in symptoms or lab values is observed. It is crucial to keep taking the medication even if you do not feel an immediate difference.
You should never stop taking mycophenolate mofetil suddenly unless directed by your doctor in an emergency. For transplant patients, stopping this medication can lead to 'rebound' immune activity, where the body quickly begins to reject the transplanted organ. This can happen even if you feel perfectly fine. If you are experiencing severe side effects, your doctor will help you slowly taper the dose or switch you to an alternative immunosuppressant. Sudden discontinuation is one of the leading causes of organ graft failure in transplant recipients.
If you miss a dose, take it as soon as you remember, provided it is not too close to your next scheduled dose. If your next dose is due within 2 hours, skip the missed dose and resume your normal schedule. Do not double the dose to catch up, as this can lead to toxic levels of the drug in your blood and increase the risk of severe side effects like bone marrow suppression. It is helpful to use a pillbox or a phone alarm to ensure you take your doses consistently every 12 hours. If you miss multiple doses, contact your transplant coordinator immediately.
Weight gain is not typically a direct side effect of mycophenolate mofetil itself. However, many patients take this drug alongside corticosteroids like prednisone, which are well-known for causing significant weight gain and increased appetite. Additionally, if the drug causes fluid retention (edema), you may notice an increase in the number on the scale. If you experience rapid weight gain or swelling in your ankles and feet, it is important to notify your healthcare provider. They can determine if the weight gain is due to medication, fluid retention, or other health factors.
Mycophenolate mofetil can be taken with many other medications, but there are several important interactions to watch out for. For example, antacids and certain phosphate binders can prevent the drug from being absorbed into your system. Some antibiotics and proton pump inhibitors (like omeprazole) can also lower the levels of the drug in your blood. Because these interactions can increase the risk of organ rejection, you must provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you use. Your doctor may need to adjust your doses or timing based on these interactions.
Yes, mycophenolate mofetil is available as a generic medication in several forms, including tablets, capsules, and oral suspension. The generic versions are generally much less expensive than the brand-name CellCept but contain the same active ingredient and meet the same FDA standards for quality and effectiveness. Many insurance plans prefer the use of generic mycophenolate. However, it is important to stay on the same manufacturer's version if possible, or notify your doctor if your pharmacy changes your generic brand, as small variations in absorption can sometimes occur.